Plasmodium vivax malaria vaccines

References

• Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 2010; 4:e774; http://dx.doi.org/10.1371/journal.pntd.0000774; PMID: 20689816
   PubMed Web of Science ®Google Scholar
• Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, Snow RW. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med 2010; 7:e1000290; http://dx.doi.org/10.1371/journal.pmed.1000290; PMID: 20563310
   PubMed Web of Science ®Google Scholar
• Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:Suppl 79 - 87; PMID: 18165478
   PubMed Web of Science ®Google Scholar
• Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Müeller I, Baird JK, Hay SI. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6 e1814
   Web of Science ®Google Scholar
• Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011; 10:378; http://dx.doi.org/10.1186/1475-2875-10-378; PMID: 22185615
   PubMed Web of Science ®Google Scholar
• PATH. 2011. Staying the course? Malaria Research and Development in a Time of Economic Uncerainty. Seattle. PATH. http://www.malariavaccine.org/files/RD-report-June2011.pdf, PATH, Seattle.
   Google Scholar
• Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128; http://dx.doi.org/10.1371/journal.pmed.0050128; PMID: 18563962
   PubMed Web of Science ®Google Scholar
• Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009; 22:430 - 5; http://dx.doi.org/10.1097/QCO.0b013e32832f14c1; PMID: 19571748
   PubMed Web of Science ®Google Scholar
• Roberts L, Enserink M. Malaria. Did they really say ... eradication?. Science 2007; 318:1544 - 5; http://dx.doi.org/10.1126/science.318.5856.1544; PMID: 18063766
   PubMed Web of Science ®Google Scholar
• Bass CC, Johns FM. The Cultivation of Malarial Plasmodia (Plasmodium Vivax and Plasmodium Falciparum) in Vitro. J Exp Med 1912; 16:567 - 79; http://dx.doi.org/10.1084/jem.16.4.567; PMID: 19867597
   PubMedGoogle Scholar
• Noulin F, Borlon C, Van Den Abbeele J, D’Alessandro U, Erhart A. 1912-2012: a century of research on Plasmodium vivax in vitro culture. Trends Parasitol 2013; 29:286 - 94; http://dx.doi.org/10.1016/j.pt.2013.03.012; PMID: 23623759
   PubMed Web of Science ®Google Scholar
• Jordan-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, Arévalo-Herrera M, Herrera S. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am J Trop Med Hyg 2005; 73:Suppl 10 - 5; PMID: 16291761
   PubMedGoogle Scholar
• Douglas RG, Sadoff J, Samant V. 2008. The Vaccine Industry. Philadelphia: Saunders.
   Google Scholar
• Moran M, Ropars A, Guzman J, Garrison C. 2005. The new landscape of neglected disease drug development., ed. TW Trust. London: The Wellcome Trust.
   Google Scholar
• Galinski MR, Barnwell JW. Plasmodium vivax: who cares?. Malar J 2008; 7:Suppl 1 S9; http://dx.doi.org/10.1186/1475-2875-7-S1-S9; PMID: 19091043
   PubMedGoogle Scholar
• Valencia SH, Rodríguez DC, Acero DL, Ocampo V, Arévalo-Herrera M. Platform for Plasmodium vivax vaccine discovery and development. Mem Inst Oswaldo Cruz 2011; 106:Suppl 1 179 - 92; http://dx.doi.org/10.1590/S0074-02762011000900023; PMID: 21881773
   PubMedGoogle Scholar
• Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, et al, RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284 - 95; http://dx.doi.org/10.1056/NEJMoa1208394; PMID: 23136909
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967; 216:160 - 2; http://dx.doi.org/10.1038/216160a0; PMID: 6057225
   PubMed Web of Science ®Google Scholar
• Sinden RE. A biologist’s perspective on malaria vaccine development. Hum Vaccin 2010; 6:3 - 11; http://dx.doi.org/10.4161/hv.6.1.9604; PMID: 19946205
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010; 78:145 - 53; http://dx.doi.org/10.1128/IAI.00740-09; PMID: 19858306
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008; 38:732 - 41; http://dx.doi.org/10.1002/eji.200737672; PMID: 18266272
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill AV. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011; 187:1347 - 57; http://dx.doi.org/10.4049/jimmunol.1100302; PMID: 21715686
   PubMed Web of Science ®Google Scholar
• Yoshida N, Potocnjak P, Nussenzweig V, Nussenzweig RS. Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med 1981; 154:1225 - 36; http://dx.doi.org/10.1084/jem.154.4.1225; PMID: 7026723
   PubMed Web of Science ®Google Scholar
• Tewari R, Spaccapelo R, Bistoni F, Holder AA, Crisanti A. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J Biol Chem 2002; 277:47613 - 8; http://dx.doi.org/10.1074/jbc.M208453200; PMID: 12244064
   PubMed Web of Science ®Google Scholar
• Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980; 151:1504 - 13; http://dx.doi.org/10.1084/jem.151.6.1504; PMID: 6991628
   PubMed Web of Science ®Google Scholar
• Warburg A, Touray M, Krettli AU, Miller LH. Plasmodium gallinaceum: antibodies to circumsporozoite protein prevent sporozoites from invading the salivary glands of Aedes aegypti. Exp Parasitol 1992; 75:303 - 7; http://dx.doi.org/10.1016/0014-4894(92)90215-V; PMID: 1426132
   PubMed Web of Science ®Google Scholar
• Lim CS, Tazi L, Ayala FJ. Plasmodium vivax: recent world expansion and genetic identity to Plasmodium simium. Proc Natl Acad Sci U S A 2005; 102:15523 - 8; http://dx.doi.org/10.1073/pnas.0507413102; PMID: 16227436
   PubMed Web of Science ®Google Scholar
• Barr PJ, Gibson HL, Enea V, Arnot DE, Hollingdale MR, Nussenzweig V. Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J Exp Med 1987; 165:1160 - 71; http://dx.doi.org/10.1084/jem.165.4.1160; PMID: 3549959
   PubMed Web of Science ®Google Scholar
• Collins WE, Nussenzweig RS, Ballou WR, Ruebush TK 2nd, Nardin EH, Chulay JD, Majarian WR, Young JF, Wasserman GF, Bathurst I, et al. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg 1989; 40:455 - 64; PMID: 2658634
   PubMed Web of Science ®Google Scholar
• Herrington DA, Nardin EH, Losonsky G, Bathurst IC, Barr PJ, Hollingdale MR, Edelman R, Levine MM. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax. Am J Trop Med Hyg 1991; 45:695 - 701; PMID: 1763796
   PubMed Web of Science ®Google Scholar
• Corradin G, Céspedes N, Verdini A, Kajava AV, Arévalo-Herrera M, Herrera S. Malaria vaccine development using synthetic peptides as a technical platform. Adv Immunol 2012; 114:107 - 49; http://dx.doi.org/10.1016/B978-0-12-396548-6.00005-6; PMID: 22449780
   PubMed Web of Science ®Google Scholar
• Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, López JA, Corradin G, Arévalo-Herrera M. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 2004; 34:1535 - 46; http://dx.doi.org/10.1016/j.ijpara.2004.10.009; PMID: 15582530
   PubMed Web of Science ®Google Scholar
• Herrera S, Bonelo A, Perlaza BL, Fernández OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuña LM, Vélez JD, et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 2005; 73:Suppl 3 - 9; PMID: 16291760
   PubMed Web of Science ®Google Scholar
• Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 2007; 75:1177 - 85; http://dx.doi.org/10.1128/IAI.01667-06; PMID: 17158893
   PubMed Web of Science ®Google Scholar
• Bell BA, Wood JF, Bansal R, Ragab H, Cargo J 3rd, Washington MA, Wood CL, Ware LA, Ockenhouse CF, Yadava A. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 2009; 27:1448 - 53; http://dx.doi.org/10.1016/j.vaccine.2008.12.027; PMID: 19138714
   PubMed Web of Science ®Google Scholar
• Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, Klein J, Bertholet S, Vedvick TS, Reed SG, et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun 2011; 79:3492 - 500; http://dx.doi.org/10.1128/IAI.05257-11; PMID: 21690242
   PubMed Web of Science ®Google Scholar
• Lumsden JM, Nurmukhambetova S, Klein JH, Sattabongkot J, Bennett JW, Bertholet S, Fox CB, Reed SG, Ockenhouse CF, Howard RF, et al. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice. Vaccine 2012; 30:3311 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.03.004; PMID: 22425788
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 2012; 7:e31472; http://dx.doi.org/10.1371/journal.pone.0031472; PMID: 22328935
   PubMed Web of Science ®Google Scholar
• Study of VMP001 and AS01B in Healthy Malaria-Naive Adults.
   Google Scholar
• Zakeri S, Razavi S, Djadid ND. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Trop 2009; 109:176 - 80; http://dx.doi.org/10.1016/j.actatropica.2008.09.012; PMID: 18950597
   PubMed Web of Science ®Google Scholar
• Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011; 366:2806 - 14; http://dx.doi.org/10.1098/rstb.2011.0091; PMID: 21893544
   PubMed Web of Science ®Google Scholar
• malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med 2011; 8:e1000398; http://dx.doi.org/10.1371/journal.pmed.1000398; PMID: 21311586
   PubMed Web of Science ®Google Scholar
• Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, et al. Shrinking the malaria map: progress and prospects. Lancet 2010; 376:1566 - 78; http://dx.doi.org/10.1016/S0140-6736(10)61270-6; PMID: 21035842
   PubMed Web of Science ®Google Scholar
• Greenwood BM, Targett GA. Malaria vaccines and the new malaria agenda. Clin Microbiol Infect 2011; 17:1600 - 7; http://dx.doi.org/10.1111/j.1469-0691.2011.03612.x; PMID: 21883665
   PubMed Web of Science ®Google Scholar
• Tomas AM, Margos G, Dimopoulos G, van Lin LH, de Koning-Ward TF, Sinha R, Lupetti P, Beetsma AL, Rodriguez MC, Karras M, et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. EMBO J 2001; 20:3975 - 83; http://dx.doi.org/10.1093/emboj/20.15.3975; PMID: 11483501
   PubMed Web of Science ®Google Scholar
• Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008; 3:e2636; http://dx.doi.org/10.1371/journal.pone.0002636; PMID: 18612426
   PubMed Web of Science ®Google Scholar
• Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005; 23:3131 - 8; http://dx.doi.org/10.1016/j.vaccine.2004.12.019; PMID: 15837212
   PubMed Web of Science ®Google Scholar
• Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 2000; 68:6618 - 23; http://dx.doi.org/10.1128/IAI.68.12.6618-6623.2000; PMID: 11083773
   PubMed Web of Science ®Google Scholar
• Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, et al. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am J Trop Med Hyg 2003; 69:536 - 41; PMID: 14695092
   PubMed Web of Science ®Google Scholar
• Galinski MR, Medina CC, Ingravallo P, Barnwell JW. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 1992; 69:1213 - 26; http://dx.doi.org/10.1016/0092-8674(92)90642-P; PMID: 1617731
   PubMed Web of Science ®Google Scholar
• Boyd M, Stratman-Thomas W, Muench H. The occurrence of gametocytes of Plasmodium vivax during the primary attack. Am J Trop Med Hyg 1936; s1–16 133–8
   Google Scholar
• Galinski MR, Meyer EV, Barnwell JW. Plasmodium vivax: modern strategies to study a persistent parasite’s life cycle. Adv Parasitol 2013; 81:1 - 26; http://dx.doi.org/10.1016/B978-0-12-407826-0.00001-1; PMID: 23384620
   PubMed Web of Science ®Google Scholar
• Chitnis CE, Sharma A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 2008; 24:29 - 34; http://dx.doi.org/10.1016/j.pt.2007.10.004; PMID: 18023618
   PubMed Web of Science ®Google Scholar
• Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, Thonier V, Carod JF, Domarle O, Colin Y, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 2010; 107:5967 - 71; http://dx.doi.org/10.1073/pnas.0912496107; PMID: 20231434
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787 - 96; http://dx.doi.org/10.1038/nri2868; PMID: 20948547
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262:1448 - 51; http://dx.doi.org/10.1126/science.8248784; PMID: 8248784
   PubMed Web of Science ®Google Scholar
• Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, Nicosia A, Colloca S, Cortese R, Folgori A, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010; 29:256 - 65; http://dx.doi.org/10.1016/j.vaccine.2010.10.041; PMID: 21029806
   PubMed Web of Science ®Google Scholar
• O’Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205:772 - 81; http://dx.doi.org/10.1093/infdis/jir850; PMID: 22275401
   PubMed Web of Science ®Google Scholar
• Moram M, Ropars A, Guzman J, Diaz J, Garrison C. 2005. The new landscape of neglected disease drug development. London: The Wellcome Trust.
   Google Scholar